Compare LYFT Inc (LYFT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? LYFT Inc trades at $16.33 (market cap $6.20B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: LYFT Inc is far larger — about 6.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 48 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LYFT | MRVI | |
|---|---|---|
Market Cap | $6.20B | $972.90M |
Volume | 12,306,511 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $24.57 | $9.00 |
52-Week Low | $12.65 | $2.83 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $5.67B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.48, up 2.3% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 2.38 and net income margin of 42.32%. Recent developments include European expansion and a $272.5M legal settlement. Cash flow improved significantly to $891M in 2025 from negative levels in prior years, while revenue grew to $6.32B.
Outlook remains positive with analyst consensus target of $18.07, though mixed earnings performance and regulatory risks persist. The stock offers value with low valuation multiples but faces competition and execution challenges in international markets. Recent technical indicators show overbought conditions near resistance at $17.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
